Alpha Tau's Pancreatic Cancer Data Set for High-Profile Debut at DDW 2026 — Alpha Tau Medical Ltd.

Event summary

Alpha Tau's Alpha DaRT pancreatic cancer data accepted for oral presentation at DDW 2026, marking first major gastroenterology conference presentation of this data.
Presentation based on combined results from two clinical trials at Hadassah Medical Center in Jerusalem.
Session scheduled for May 2, 2026, led by Principal Investigator Dr. Harold Jacob.
Data comes from two first-in-human trials of alpha-emitting radionuclide for pancreatic adenocarcinoma.
Company's IMPACT pilot study currently enrolling patients in the U.S.

The big picture

Alpha Tau's presentation at DDW 2026 represents a strategic milestone in positioning its Alpha DaRT technology within the gastroenterology community. With pancreatic cancer having a high mortality rate and limited treatment options, particularly for inoperable patients, Alpha Tau aims to carve out a niche in this challenging therapeutic area. The acceptance of this abstract for an oral presentation underscores the growing recognition of Alpha DaRT's potential, though the company still faces significant hurdles in translating clinical data into commercial success.

What we're watching

Clinical Validation: Whether the DDW presentation will generate sufficient clinical validation to accelerate Alpha DaRT's adoption in pancreatic cancer treatment.
Regulatory Pathway: How the data presented at DDW may influence the design and timing of Alpha Tau's future pivotal study.
Market Differentiation: The pace at which Alpha DaRT can establish itself as a differentiated treatment option in the pancreatic cancer space.